arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BIOMARIN PHARMACEUTICAL INC

BMRN
$56.12 ▼ -1.01 (-1.77%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
73 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Neutral
auto_awesome

Analytical Summary

BIOMARIN PHARMACEUTICAL INC shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $10.9B
Dividend Yield —
Revenue Growth 32.0% ↗
Op. Margin -8.0% ↘
ROIC -0.7% ↘
FCF / Share $0.83 ↗
Trailing P/E —
Price / Book 1.7x
FCF Yield 1.5%
Debt / Equity 0.67
info Valuation on last close. End-of-day price, Nov 5, 2026.

73-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.02B
↑ +32.0% —
Net Income Profit after all expenses
$-122.83M
↓ -299.5% —
Operating Margin Operating profit as % of sales
-8.0%
↓ -171.5% 63th
FCF / Share Free cash flow per share
$0.83
↑ +14.7% —
Long-Term Debt Long-term obligations
$4.17B
— -0.3% —

Health Breakdown

Profitability ↑
71
Returns
55
Financial Health
94
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 73 quarters